CaroGen targeting breakthrough immunotherapy

CaroGen’s lead product is an immunotherapy that targets Hepatitis B. The company is also working on immunotherapies for ovarian cancer and for colorectal cancer.

Bijan Almassian is president and CEO. His small team — five full-time employees and five part-timers — occupies space in UConn Health’s Cell and Genome Building in Farmington.